StreetAlpha.app
Home › Stocks › ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR)

Healthcare
$42.99
▼ −2.76%
LAST CLOSE · NOV 17

Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease genes, mainly for metabolic and liver conditions. It last closed at $42.99 on Nov 17, down 2.76% on the day. ARWR reports earnings on Thu, Feb 4, 2027. The average 12-month price target from 6 analysts is $99.83 (+132.2% from the last close), with a high of $115.00 and a low of $74.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in ARWR, 33% of them bullish and 67% bearish. In the past 30 days there were 2 dark pool prints totaling $2.5M, the largest $1.5M.

AI Auto Pilots
Is ARWR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$450.8M
−45.6% vs a year ago
Net income
−$724.2M
−160.6% margin
EPS (diluted)
−$5.11
Free cash flow
−$283.9M
−63.0% margin
Valuation
Market cap
$6.1B
141.4M shares
P/E
–
No P/E while losing money
Price to sales
13.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$62.7M
At Sep 30
Shareholder equity
$50.3M
Shares outstanding
141.4M
At Nov 5
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2022: $243.2M$243.2MFY2022FY2023: $240.7M$240.7MFY2023FY2024: $3.6M$3.6MFY2024FY2025: $829.4M$829.4MFY2025FY2026: $450.8M$450.8MFY2026

From ARWR's SEC filings, latest 10-K for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 4
2027 · Time not announced
Consensus EPS forecast
-$1.46
$40.8M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
5 Buy1 Hold0 Sell
Each firm's latest rating on ARWR in the past 90 days
Average 12-month target
$99.83
▲ 132.2% upside

Based on 6 analysts who set a price target on ARWR in the past 90 days. The average target is $99.83, with a high of $115.00 and a low of $74.00, compared with the last close of $42.99.

Low $74.00Avg $99.83High $115.00
Blue marker: last close $42.99
Highest target$115.00
Average target$99.83
Lowest target$74.00
Latest rating changes
CitigroupTarget lowered
Nov 17Buy$108 → $105
RBC CapitalReiterated
Nov 13Buy$100
StifelTarget lowered
Nov 13Buy$98 → $96
UBSAssumed coverage
Oct 15Buy$109
Goldman SachsReinstated
Sep 24Hold$74
DateFirmActionRatingPrice target
Nov 17CitigroupTarget loweredBuy$108 → $105
Nov 13RBC CapitalReiteratedBuy$100
Nov 13StifelTarget loweredBuy$98 → $96
Oct 15UBSAssumed coverageBuy$109
Sep 24Goldman SachsReinstatedHold$74
Loading…

Technical Analysis

ARWR · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 28% below its 20 day and 43% below its 50 day average. It is 65% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot S1 at $41.86, and the nearest resistance the Pivot at $43.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 7.1%/day
Key levels
$95.4952 week high+122.1%
$72.89100 day average+69.6%
$70.81200 day average+64.7%
$61.6450 day average+43.4%
$60.46Swing high (Oct 21)+40.6%
$55.0020 day average+27.9%
$44.34Pivot R1+3.1%
$43.20Pivot+0.5%
$42.99Last close
$41.86Pivot S1−2.6%
$37.0652 week low−13.8%
Indicators
RSI (14)20.85Oversold below 30Oversold
MACD-4.81Below its signal lineBearish
Stochastic8.0Near the bottom of its rangeOversold
ADX (14)39.2Trending down
Williams %R-95.4Oversold below −80, overbought above −20Oversold
CCI (20)-144.5Oversold below −100, overbought above 100Oversold
Rate of change−27.8%Change over 10 sessionsBearish
ATR (14)$3.07Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARWR

What happened before

See how ARWR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish1 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow ARWR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARWR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
1
33%
Bearish
2
67%
Date span
Sep 14 – Oct 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.5M
Largest print
$1.5M
Loading…

ARWR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●241 buying vs 250 selling
  • ▼Held by funds -1.6 pts
  • ▼Funds holding -18
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding487505−3.6%
In funds' top 10990.0%
Held by funds83.2%84.8%−1.6 pts
New / increased67 / 174124 / 154−13.3%
Reduced / sold out170 / 80156 / 58+16.8%
Put/call ratio0.240.35−29.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARWR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARWR is in one of them and how their past ARWR trades turned out.

ARWR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARWR in an article yet. Here's the latest on the wider market.

ARWR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 24
Who traded ARWR · since 2023
Latest 1 filing
$1K – $15KTraded Jan 31, 2023Filed Feb 24, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KJan 31, 2023Feb 24, 202324 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biopharmaceutical company based in Pasadena, California. It develops medicines that use RNA interference to switch off genes that drive disease, aiming at conditions that traditional drugs have struggled to treat. Its approved product, REDEMPLO, treats adults with familial chylomicronemia syndrome, a rare genetic disorder that raises triglyceride levels. The company's pipeline targets lipid and liver diseases, and it licenses its technology to other drugmakers.

Headquarters
Pasadena, CA
Founded
1989